Meta AnalysisID 2304
脑脊液半乳甘露聚糖检测诊断中枢神经系统曲霉病：一项系统评价与Meta分析
CRD42022296331
For patients with central nervous system (CNS) aspergillosis, proven by histopathology and/or radiographic imaging, what is the diagnostic accuracy (sensitivity and specificity) of galactomannan detection in the cerebros
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2304
- Evidence Id
- 10862
- Core Evidence Id
- 10862
- Source Meta Analysis Id
- 2252
- Herb2 Meta Analysis Id
- HBMA002252
- Crd Id
- CRD42022296331
- Title
- Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a systematic review and meta-analysis
- Review Question
- For patients with central nervous system (CNS) aspergillosis, proven by histopathology and/or radiographic imaging, what is the diagnostic accuracy (sensitivity and specificity) of galactomannan detection in the cerebrospinal fluid (CSF)?
- Study Type Included
- Inclusion: prospective and retrospective cohort studies using any galactomannan assay on CSF samples, either alone or in combination with other testing modalities. Exclusion: case reports; subject reviews; case series with < 5 CNS aspergillosis patients.
- Condition Being Studied
- CNS infections, aspergillosis, diagnostic test accuracy
- Participant
- Inclusion: immunocompetent and immunocompromised patients, adult and pediatric. Exclusion: non-humans, allergic aspergillosis, invasive pulmonary aspergillosis, aspergillosis outside the CNS.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion: CSF galactomannan used singularly or in combination with other tests for the diagnosis of CNS aspergillosis. Exclusion: 1, 3-beta-D-glucan alone, Aspergillus PCR alone, or other non-galactomannan-based diagnostic techniques used alone in the diagnosis of CNS aspergillosis.
- Comparator Control
- The 2019 EORTC/MSG diagnostic criteria, which classifies patients into three groups as: proven, probably, or possibly suffering from invasive aspergillosis. To construct 2x2 tables, we defined possible aspergillosis as “no CNS aspergillosis”; and proven and probable aspergillosis as “having CNS aspergillosis”. This decision was made to be consistent with a prior Cochrane review of diagnostic test accuracy in pulmonary aspergillosis. References: 1. Leeflang MMG, Debets‐Ossenkopp YJ, Wang J, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD007394. DOI: 10.1002/14651858.CD007394.pub2. 2. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008.
- Main Outcome
- The primary goal of the study is the assessment of the accuracy of galactomannan testing of CSF in the diagnosis of CNS aspergillosis at different cut-offs for test positivity. Primary outcome is the validation or disqualification of galactomannan testing as a suitable biomarker test to diagnose patients with CNS aspergillosis. Measures of effect Sensitivity, specificity
- Outcome Measure
- Additional Outcome
- The secondary outcomes are the determination of galactomannan test characteristics in immunocompetent and immunocompromised patients. Measures of effect Sensitivity, specificity
- Study Method
- Diagnostic, Meta-analysis, Systematic review
- Keyword
- Central Nervous System; Galactose; Humans; Mannans; Neuroaspergillosis; galactomannan
- Contact
- Adam S. Komorowski [email protected]
- Organisational Affiliation
- Division of Medical Microbiology, McMaster University, Hamilton, ON, Canada
- Funding Source
- None Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> None
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Canada
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-12-04
- Registration Date
- 2022-01-04
- Anticipated Start Date
- 2022-01-06
- Anticipated Completion Date
- 2022-05-01
- Title Cn
- 脑脊液半乳甘露聚糖检测诊断中枢神经系统曲霉病：一项系统评价与Meta分析
- Title En
- Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a systematic review and meta-analysis
- Bilingual Status
- complete